AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
8113.T
ACCE-researched

Unicharm Corporation (8113.T) fair value

Consumer Defensive · Household & Personal Products · TSE · Japan
¥1019.50+1.44%
Market cap ¥1.75TNext earnings 2026-11-06Updated Oct 24, 2026 · valuation updating
Our verdict
No fair value
We are missing the financial data our models need for this company. It will appear once the data arrives.
Not valued: there are no financial statements on file yet.
ACCE opinionUnicharm Corporation (8113.T)
Fair value
Not available
ACCE price target
¥969
Rating
Not rated
Horizon
12 months
ACCE price target published on 22 Oct 2026, 16:00 CEST.
Price used: ¥1020 at the close on 23 Oct 2026, 08:30 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
64
out of 100
P/E
27.3x
forward 5.8x
1-year return
+2.1%
Dividend yield
2.19%

Unicharm Corporation in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Unicharm makes disposable hygiene products, mainly baby diapers, feminine care pads and adult incontinence products, sold under the Moony and Sofy brands across Japan, China, Southeast Asia and beyond. Its structural edge is brand strength in a category where repeat purchase is habitual and private-label competition has been limited, which supports a 40.0% gross margin. Growth should come from Asian markets where diaper and adult incontinence penetration is still low relative to Japan, and from the ageing-population tailwind in adult care. The stock screens oddly: trailing P/E is 28.0 while forward P/E is 5.7, a gap that usually reflects a sharp expected jump in earnings or a one-off charge rolling out of the trailing figures, and that is the first thing to verify. Revenue growth of 6.9% and a 13.1% operating margin are respectable for a defensive staple, though ROE of 8.3% is modest and needs explaining. Index membership is none, so liquidity and ownership base are worth checking before sizing.

AI-assisted·How I use AIWritten Oct 23, 2026
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
  • moderate
    Price above ACCE target
    Shares trade 5.2% above the ACCE price target of ¥969.00 (price ¥1019.50), so the stock already reflects part of the expected upside.
  • moderate
    Multiple well above forward estimate
    Trailing P/E is 28.0 against a forward P/E of 5.7, a gap that depends heavily on the reliability of the forward earnings estimate.

AI research notes

AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-10-22 · prices to Oct 23, 2026
Why it could do well
  • Revenue grew 6.9% over the latest year, and the company still produced JPY 58.3B of free cash flow over the last twelve months.
  • Debt to equity of 0.01 means the balance sheet carries almost no borrowing, leaving little financial risk for shareholders.
  • Earnings per share beat expectations by 12.0%, with 12.35 reported against 11.03 expected, and analysts' mean target sits 11.5% above the share price.
Why it could disappoint
  • Trailing P/E of 28.0x is steep for a company whose return on equity is only 8.3%.
  • Revenue has shrunk by an average of 25.6% a year over five years, so the recent 6.9% gain may not be a lasting recovery.
  • A net margin of 6.7% leaves little room for error if costs rise or prices fall in a competitive consumer market.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where 8113.T's valuation models land
Price
¥1019.50
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Recent performance

1 week
+1.2%
1 month
+6.2%
3 months
+6.5%
6 months
+7.1%
YTD
+13.9%
1 year
+2.1%

Recommendation history, last 12 months

DateTypeNewPreviousPrice
22 Oct 2026, 16:00 CESTACCE price target¥969first publication¥1005

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

This security trades in JPY. Exchange-rate movements can increase or reduce the result in your own currency.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full 8113.T page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth56Value72Quality63Momentum63Total64
Valuation
Trailing P/E
27.3x
Forward P/E
5.8x
PEG
1.03
P/B
no data
EV / Revenue
no data
Book value/sh
no data
Enterprise value
no data
Profitability
ROE
8.3%
FCF yield
3.37%
ROIC
no data
Health and risk
Debt / equity
0.01
Dividend yield
2.19%
Beta
no data

Price

+3.6% · 1Y

Ask anything about 8113.T

Answered from Unicharm Corporation fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 60% of peers
low 18.4x27.3xhigh 52.6x
ROEbetter than 25% of peers
low -3%8%high 164%
Div yieldbetter than 50% of peers
low 0.5%2.2%high 5.9%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
8113.T Unicharm Corporation¥1019.50--27.3x8.3%6364
CLX Clorox Company (The) Common Stock$88.66$6732% above18.4x163.8%6441
MARICO.NS Marico Limited₹775.00--52.6x-8557
PUIG.MC Puig Brands SA€19.29€1618% above18.7x15.6%7261
4911.T Shiseido Company, Limited¥3569.00----3.1%5266
GODREJCP.NS Godrej Consumer Products Limited₹860.20₹313175% above45.8x15.1%7548
DABUR.NS Dabur India Limited₹368.00--32.7x-8551

Sector report card

Where 8113.T ranks against its sector peers on each metric.

Computing percentiles…